Top

Published in:

01-10-2009

Additive Protective Effects of Donepezil and Nicotine Against Salsolinol-Induced Cytotoxicity in SH-SY5Y Cells

Authors: Jharna R. Das, Yousef Tizabi

Published in: Neurotoxicity Research | Issue 3/2009

Abstract

Although the etiology of Parkinson’s disease (PD) remains elusive, a number of toxins including elevated salsolinol, an endogenous metabolite of dopamine may contribute to its pathology. It was reported recently that nicotine may have protective effects against salsolinol-induced toxicity in human neuroblastoma derived SH-SY5Y cells and that these effects of nicotine are mediated by nicotinic receptors. Donepezil (Aricept) is a reversible non-competitive acetylcholinesterase inhibitor that is approved for use in mild to moderate Alzheimer’s disease. The increase in acetylcholine concentrations is believed to be the major contributory factor in donepezil’s therapeutic efficacy. However, cholinesterase inhibitors may also directly interact with nicotinic receptors and possess neuroprotective properties. In this study, we sought to determine whether donepezil may have protective effects against salsolinol-induced toxicity in SH-SY5Y cells and whether the combination of donepezil and nicotine may result in additive protection. Moreover, it was of interest to elucidate the role of nicotinic receptors as well as cell cycle and apoptosis in mechanism of action of these compounds. SH-SY5Y cells were exposed to 0.6 mM salsolinol with and without various drug pretreatments for 48 h. Nicotine (50 μM) resulted in approximately 54% protection and donepezil (5 μM) resulted in approximately 40% protection, and the combination of the two resulted in an additive (approximately 93%) protection against salsolinol-induced toxicity. Salsolinol caused an arrest of the cells in G₁-phase of cell cycle and an increase in apoptotic indices that were blocked by the combination of donepezil and nicotine. Mecamylamine, a non-selective nicotinic receptor antagonist completely blocked the effects of nicotine and partially attenuated the effects of donepezil. A combination of atropine, a muscarinic receptor antagonist and mecamylamine completely blocked the effects of donepezil, indicating involvement of both nicotinic and muscarinic receptors in donepezil’s actions. The findings suggest a therapeutic potential for the combination of donepezil and nicotine in PD.

Akaike A (2008) Preclinical evidence of neuroprotection by cholinesterase inhibitors. Eur J Pharmacol 588:189–197PubMedCrossRef

Akasofu S, Sawada K, Kosasa T, Hihara H, Ogura H, Akaike A (2006) Donepezil attenuates excitotoxic damage induced by membrane depolarization of cortical neurons exposed to veratridine. Alzheimer Dis Assoc Disord 20:S8–S11CrossRef

Bollimuntha S, Ebadi M, Singh BB (2006) TRPC1 protects human SH-SY5Y cells against salsolinol-induced cytotoxicity by inhibiting apoptosis. Brain Res 1099:141–149PubMedCrossRef

Copeland RL Jr, Leggett YA, Kanaan YM, Taylor RE, Tizabi Y (2005) Neuroprotective effects of nicotine against salsolinol-induced cytotoxicity: implications for Parkinson’s disease. Neurotox Res 8:289–293PubMedCrossRef

Copeland RL Jr, Das JR, Kanaan YM, Taylor RE, Tizabi Y (2007) Antiapoptotic effects of nicotine in its protection against salsolinol-induced cytotoxicity. Neurotox Res 12:61–70PubMedCrossRef

Dajas-Bailador FA, Soliakov L, Wonnacott S (2002) Nicotine activates the extracellular signal-regulated kinase I/2 via the α7 nicotinic acetylcholine receptor and protein kinase A, in SH-SY5Y cells and hippocampal neurones. J Neurochem 80:520–530PubMedCrossRef

Di Angelantonio S, Bernardi G, Mercuri NB (2004) Donepezil modulates nicotinic receptors of substantia nigra dopaminergic neurones. Br J Pharmacol 141:644–652PubMedCrossRef

Ebadi M, Pfeffer RF (2005) Parkinson’s disease, 1st edn. Taylor and Francis, London

Gorell JM, Rybicki BA, Johnson CC, Peterson EL (1999) Smoking and Parkinson’s disease: a dose–response relationship. Neurology 52:115–119PubMed

Guan ZZ, Yu WF, Nordberg A (2003) Dual effects of nicotine on oxidative stress and neuroprotection in PC12 cells. Neurochem Int 43:243–249PubMedCrossRef

Hayslett RL, Tizabi Y (2003) Effects of donepezil on DOI-induced head twitch response in mice: implications for Tourette syndrome. Pharmacol Biochem Behav 76:409–415PubMedCrossRef

Hejmadi MV, Dajas-Bailador F, Barns SM, Jones B, Wonnacott S (2003) Neuroprotection by nicotine against hypoxia-induced apoptosis in cortical cultures involves activation of multiple nicotinic acetylcholine receptor subtypes. Mol Cell Neurosci 24:779–786PubMedCrossRef

Hernan MA, Takkouche B, Caamano-Isorna F, Gestal-Otero JJ (2002) A meta-analysis of coffee drinking, cigarette smoking, and the risk of Parkinson’s disease. Ann Neurol 52:276–284PubMedCrossRef

Khwaja M, McCormack A, McIntosh JM, Di Monte DA, Quik M (2007) Nicotine partially protects against paraquat-induced nigrostriatal damage in mice; link to alpha6beta2* nAChRs. J Neurochem 100:180–190PubMedCrossRef

Kihara T, Shimohama S, Urushitani M, Sawada H, Kimura J, Kume T, Maeda T, Akaike A (1998) Stimulation of alpha4 beta2 nicotinic acetylcholine receptors inhibits beta-amyloid toxicity. Brain Res 792:331–334PubMedCrossRef

Liu Q, Zhao B (2004) Nicotine attenuates beta-amyloid peptide-induced neurotoxicity, free radical and calcium accumulation in hippocampal neuronal cultures. Br J Pharmacol 141:746–754PubMedCrossRef

Maruyama W, Yi H, Takahashi T, Shimazu S, Ohde H, Yoneda F, Iwasa K, Naoi M (2004) Neuroprotective function of R-(−)-1-(benzufuran-2-yl)-2-propylaminopentane, [R-(−)-BPAP], against apoptosis induced by N-methyl(R)salsolinol, an endogenous dopaminergic neurotoxin, in human dopaminergic neuroblastoma SH-SY5Y cells. Life Sci 75:107–117PubMedCrossRef

Naoi M, Maruyama W, Nagy GM (2004) Dopamine-derived salsolinol derivatives as endogenous monoamine oxidase inhibitors: occurrence, metabolism and function in human brains. Neurotox Res 25:193–204CrossRef

Peng J, Stevenson FF, Oo ML, Andersen JK (2009) Iron-enhanced paraquat-mediated dopaminergic cell death due to increased oxidative stress as a consequence of microglial activation. Free Radic Biol Med 46:312–320PubMedCrossRef

Picciotto MR, Zoli M (2008) Neuroprotection via nAChRs: the role of nAChRs in neurodegenerative disorders such as Alzheimer’s and Parkinson’s disease. Front Biosci 13:492–504PubMedCrossRef

Quik M, McIntosh JM (2006) Striatal alpha6* nicotinic acetylcholine receptors: potential targets for Parkinson’s disease therapy. J Pharmacol Exp Ther 316:481–489PubMedCrossRef

Quik M, Bordia T, McIntosh JM (2004) Loss of α-conotoxin MII- and A85380-sensitive nicotinic receptors in Parkinson’s disease striatum. J Neurochem 88:668–679PubMedCrossRef

Quik M, O’Leary K, Tanner CM (2008) Nicotine and Parkinson’s disease: implications for therapy. Mov Disord 23:1641–1652PubMedCrossRef

Stevens TR, Krueger SR, Fitzsimonds RM, Picciotto MR (2003) Neuroprotection by nicotine in mouse primary cortical cultures involves activation of calcineurin and l-type calcium channel inactivation. J Neurosci 23:10093–10099PubMed

Storch A, Schrattenholz A, Cooper JC, Abdel Ghani EM, Gutbrod O, Weber KH, Reinhardt S, Lobron C, Hermsen B, Soskiç V et al (1995) Physostigmine, galanthamine and codeine act as ‘noncompetitive nicotinic receptor agonists’ on clonal rat pheochromocytoma cells. Eur J Pharmacol 290:207–219PubMedCrossRef

Storch A, Ott S, Hwang Y, Ortmann R, Hein A, Frenzel S, Matsubara K, Ohta S, Wolf H, Schwarz J (2002) Selective dopaminergic neurotoxicity of isoquinoline derivatives related to Parkinson’s disease: studies using heterologous expression systems of the dopamine transporter. Biochem Pharmacol 63:909–920PubMedCrossRef

Takada-Takatori Y, Kume T, Ohgi Y, Izumi Y, Niidome T, Fujii T, Sugimoto H, Akaike A (2008) Mechanism of neuroprotection by donepezil pretreatment in rat cortical neurons chronically treated with donepezil. J Neurosci Res 86:3575–3583PubMedCrossRef

Tatton NA (2000) Increased caspase 3 and Bax immunoreactivity accompany nuclear GAPDH translocation and neuronal apoptosis in Parkinson’s disease. Exp Neurol 166:29–43PubMedCrossRef

Tizabi Y, Mastropaolo J, Park CH, Riggs RL, Powell D, Rosse RB, Deutsch SI (1998) Both nicotine and mecamylamine block dizocilpine-induced explosive jumping behavior in mice: psychiatric implications. Psychopharmacology (Berl) 140:202–205CrossRef

Tizabi Y, Russell LT, Johnson M, Darmani NA (2001) Nicotine attenuates DOI-induced head-twitch response in mice: implications for Tourette syndrome. Prog Neuropsychopharmacol Biol Psychiatry 25:1445–1457PubMedCrossRef

Tizabi Y, Al-Namaeh M, Manaye KF, Taylor RE (2003) Protective effects of nicotine on ethanol-induced toxicity in cultured cerebellar granule cells. Neurotox Res 5:315–322PubMedCrossRef

Tizabi Y, Manaye KF, Smoot DT, Taylor RE (2004) Nicotine inhibits ethanol-induced toxicity in cultured cerebral cortical cells. Neurotox Res 6:311–316PubMedCrossRef

Tizabi Y, Manaye KF, Taylor RE (2005) Nicotine blocks ethanol-induced apoptosis in primary cultures of rat cerebral cortical and cerebellar granule cells. Neurotox Res 7:319–322PubMedCrossRef

Toborek M, Son KW, Pudelko A, King-Pospisil K, Wylegala E, Malecki A (2007) ERK 1/2 signaling pathway is involved in nicotine-mediated neuroprotection in spinal cord neurons. J Cell Biochem 100:279–292PubMedCrossRef

Wirdefeldt K, Gatz M, Pawitan Y, Pedersen NL (2005) Risk and protective factors for Parkinson’s disease: a study in Swedish twins. Ann Neurol 57:27–33PubMedCrossRef

Yi H, Akao Y, Maruyama W, Chen K, Shih J, Naoi M (2006) Type A monoamine oxidase is the target of an endogenous dopaminergic neurotoxin, N-methyl(R)salsolinol, leading to apoptosis in SH-SY5Y cells. J Neurochem 96:541–549PubMedCrossRef

Title: Additive Protective Effects of Donepezil and Nicotine Against Salsolinol-Induced Cytotoxicity in SH-SY5Y Cells
Authors: Jharna R. Das
Yousef Tizabi
Publication date: 01-10-2009
Publisher: Springer-Verlag
Published in: Neurotoxicity Research / Issue 3/2009
Print ISSN: 1029-8428
Electronic ISSN: 1476-3524
DOI: https://doi.org/10.1007/s12640-009-9040-2

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Additive Protective Effects of Donepezil and Nicotine Against Salsolinol-Induced Cytotoxicity in SH-SY5Y Cells

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 3/2009

Versatile Somatic Gene Transfer for Modeling Neurodegenerative Diseases

Mutant α-Synuclein Overexpression Mediates Early Proinflammatory Activity

CXCR4 and CXCL12 Expression is Increased in the Nigro-Striatal System of Parkinson’s Disease

Commentary: Regulating proNGF Action: Multiple Targets for Therapeutic Intervention

Nur(R1)turing a Notion on the Etiopathogenesis of Parkinson’s Disease

Metabolic Control Analysis in a Cellular Model of Elevated MAO-B: Relevance to Parkinson’s Disease